These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 33445986)

  • 21. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
    Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
    ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspectives on the development of first-in-class protein degraders.
    Rambacher KM; Calabrese MF; Yamaguchi M
    Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Protein induced proximity and targeted degradations by new degraders: concepts, developments, challenges for clinical applications].
    Reboud-Ravaux M
    Biol Aujourdhui; 2024; 218(1-2):41-54. PubMed ID: 39007776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
    Dann GP; Liu H; Nowak RP; Jones LH
    Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
    Liang Y; Nandakumar KS; Cheng K
    Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PROTACs: Promising approach for anticancer therapy.
    Kaur SD; Bedi N; Kumar D; Kapoor DN
    Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
    Chaudhry C
    J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advancing targeted protein degrader discovery by measuring cereblon engagement in cells.
    Zerfas BL; Huerta F; Liu H; Du G; Gray NS; Jones LH; Nowak RP
    Methods Enzymol; 2023; 681():169-188. PubMed ID: 36764756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
    Belcher BP; Ward CC; Nomura DK
    Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation.
    Riching KM; Caine EA; Urh M; Daniels DL
    Chem Soc Rev; 2022 Jul; 51(14):6210-6221. PubMed ID: 35792307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches.
    Scholes NS; Mayor-Ruiz C; Winter GE
    Cell Chem Biol; 2021 Jul; 28(7):1048-1060. PubMed ID: 33811812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational discovery of molecular glue degraders via scalable chemical profiling.
    Mayor-Ruiz C; Bauer S; Brand M; Kozicka Z; Siklos M; Imrichova H; Kaltheuner IH; Hahn E; Seiler K; Koren A; Petzold G; Fellner M; Bock C; Müller AC; Zuber J; Geyer M; Thomä NH; Kubicek S; Winter GE
    Nat Chem Biol; 2020 Nov; 16(11):1199-1207. PubMed ID: 32747809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Translation of Targeted Protein Degraders.
    Kong NR; Jones LH
    Clin Pharmacol Ther; 2023 Sep; 114(3):558-568. PubMed ID: 37399310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Key Considerations in Targeted Protein Degradation Drug Discovery and Development.
    Qin L; Dai H; Wang J
    Front Chem; 2022; 10():934337. PubMed ID: 35978859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.